Pandey et al., 2021 - Google Patents
Cyclotron production of PET radiometals in liquid targets: Aspects and prospectsPandey et al., 2021
View HTML- Document ID
- 8916155443511155050
- Author
- Pandey M
- DeGrado T
- Publication year
- Publication venue
- Current radiopharmaceuticals
External Links
Snippet
The present review describes the methodological aspects and prospects of the production of Positron Emission Tomography (PET) radiometals in a liquid target using low-medium energy medical cyclotrons. The main objective of this review is to delineate and discuss the …
- 238000004519 manufacturing process 0 title abstract description 98
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
- G21G2001/0042—Technetium
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G4/00—Radioactive sources
- G21G4/04—Radioactive sources other than neutron sources
- G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/0005—Isotope delivery systems
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pandey et al. | Cyclotron production of PET radiometals in liquid targets: Aspects and prospects | |
| Eychenne et al. | Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight” | |
| Domnanich et al. | 47 Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes | |
| US11266975B2 (en) | Solution target for cyclotron production of radiometals | |
| Notni et al. | Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals | |
| Boros et al. | Chemical aspects of metal ion chelation in the synthesis and application antibody‐based radiotracers | |
| Domnanich et al. | Production and separation of 43 Sc for radiopharmaceutical purposes | |
| Ferrier et al. | Radiochemical aspects of alpha emitting radionuclides for medical application | |
| Huclier-Markai et al. | Promising scandium radionuclides for nuclear medicine: a review on the production and chemistry up to in vivo proofs of concept | |
| Do Carmo et al. | Production of radiometals in liquid targets | |
| Rösch et al. | Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS | |
| Guhlke et al. | Simple new method for effective concentration of 188Re solutions from alumina-based 188W—188Re Generator | |
| CA2570191C (en) | Radionuclides for medical use | |
| Loveless et al. | Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47 Sc | |
| Valdovinos et al. | Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets | |
| JP6429899B2 (en) | Production of 43Sc radionuclide and its radiopharmaceutical for use in positron emission tomography | |
| Bartoś et al. | Search of ligands suitable for 212 Pb/212 Bi in vivo generators | |
| Egorova et al. | Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals | |
| Choiński et al. | Prospects for the production of radioisotopes and radiobioconjugates for theranostics | |
| Lin et al. | Fully automated preparation of 68Ga-PSMA-11 at curie level quantity using cyclotron-produced 68Ga for clinical applications | |
| JP7017511B2 (en) | Isotope purification method | |
| Eppard | Pre-therapeutic dosimetry employing scandium-44 for radiolabeling PSMA-617 | |
| Knapp et al. | Re-emergence of the important role of radionuclide generators to provide diagnostic and therapeutic radionuclides to meet future research and clinical demands | |
| Ermert et al. | Radiopharmaceutical sciences | |
| Knapp et al. | Radionuclide generator systems represent convenient production systems to provide therapeutic radionuclides |